Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Aidan C Li, Jing Zhao, Ramon Hartage, Yunxiang Zhang, Chao Zhao, Xiaoxian Li, Anil V. Parwani, Zhongliang Ma
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Patients with HER2-positive breast cancer commonly receive anti-HER2 neoadjuvant chemotherapy and pathologic complete response (pCR) can be achieved in up to half of the patients. HER2 protein expression detected by immunohistochemistry (IHC
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Autor:
Xin-lan Luo, Fangping Xu, Hongmei Wu, Yi-Fang Zhang, Ke-Ping Zhang, Jie Xu, Kun Wang, Ming-hui Zhang, Xiao-Xu Long, Danyi Lin, Jie Chen, Yan-hui Liu
Publikováno v:
Breast Cancer Research and Treatment. 166:757-764
The updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing have made some major changes in HER2 fluorescence in situ hybridization (FIS
Autor:
D. Craig Allred, Eslie Dennis, Hiroshi Matsumoto, Jim Ranger-Moore, Hiroaki Nitta, Izumi Takeyoshi, Sasagu Kurozumi, Tetsunari Oyama, Kenichi Inoue, Mary Padilla, Jun Horiguchi, Masafumi Kurosumi
Publikováno v:
Breast Cancer Research and Treatment
HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and prot
Autor:
Aye-Aye Thike, Cindy Lim, Puay Hoon Tan, Sau Yeen Loke, David F. Callen, Yoon Sim Yap, Iain Beehuat Tan, Ann S. G. Lee, Jeffrey Chun Tatt Lim, Swee-Ho Lim, Claire Hian Tzer Chan, Aldo Prawira, Sarah B. H. Ng, Prabhakaran Munusamy, Kong-Wee Ong, Wei-Sean Yong
Publikováno v:
Breast cancer research and treatment. 171(3)
The purpose of the study was to improve the understanding of NF1-associated breast cancer, given the increased risk of breast cancer in this tumour predisposition syndrome and the limited data. We identified 18 women with NF1 and breast cancer at our
Autor:
Jeremy Thomas, J.M. Dixon, J. Keys, Laura M. Arthur, Andrew H. Sims, Lorna Renshaw, Arran K Turnbull, Mark R. Lackner, Timothy R. Wilson
Publikováno v:
Breast Cancer Research and Treatment. 147:211-219
The phosphatidylinositol-3-kinase pathway plays an important role in proliferation, migration and survival in breast cancer and may play a role in resistance to endocrine therapy. Pathway activation occurs as a result of mutations in PIK3CA or loss o
Autor:
Emad A. Rakha, Paul M. Moseley, Alice C. Durham, Tarek M. A. Abdel-Fatah, Christopher C. Nolan, Andrew R. Green, Ian O. Ellis, Fabrício F. T. Barros, Stephen Chan
Publikováno v:
Breast Cancer Research and Treatment. 144:273-285
HER2 plays an important role in breast cancer progression and provides predictive and prognostic information. HER2 receptor family members function through dimerisation, which can lead to impact on cell function, growth and differentiation; however,
Publikováno v:
Breast cancer research and treatment. 161(2)
Neoadjuvant chemotherapy (NCT) plus anti-HER2 agents are the standard of care for locally advanced HER2-positive breast cancer. The aim of this study was to evaluate the prevalence and prognostic impact of HER2 loss in patients with HER2-positive dis
Autor:
Jose R. Alemar, Denise A. Yardley, Brooke R. Daniel, Patrick B. Murphy, Robyn R. Young, John D. Hainsworth
Publikováno v:
Breast cancer research and treatment. 160(1)
Determination of HER2 status by testing circulating tumor cells (CTCs), compared to sampling tumor biopsies, may improve patient management by allowing ongoing assessment of HER2 status during the disease course. The PRO Onc assay (Prometheus Laborat
Publikováno v:
Breast Cancer Research and Treatment. 134:1095-1102
In 2009, ASCO/CAP expanded its human epidermal growth factor receptor type 2 (HER2) testing guideline to define HER2 genetic heterogeneity (GH). However, the clinical significance of GH is unclear. We investigated the impact of HER2 GH on HER2 testin